Chromocell Corporation - Articles and news items

Astellas and Chromocell to develop neuropathic pain treatments

Industry news / 30 September 2015 / Victoria White

Astellas has obtained worldwide rights to commercialise Chromocell’s lead compound, CC8464 – an oral, peripherally-acting inhibitor of NaV1.7…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+